J
Julia Chapman
Researcher at University of Kansas
Publications - 17
Citations - 1365
Julia Chapman is an academic researcher from University of Kansas. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 12, co-authored 17 publications receiving 1204 citations. Previous affiliations of Julia Chapman include Munroe Regional Medical Center.
Papers
More filters
Journal ArticleDOI
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
TL;DR: Investigation of the use of intravenous ascorbic acid in conjunction with chemotherapy for ovarian cancer, starting from preclinical models and culminating in a human trial, which demonstrated a significant reduction in chemotherapy-induced adverse effects in patients receiving asCorbate.
Journal ArticleDOI
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Gini F. Fleming,Michael W. Sill,Michael W. Sill,Kathleen M. Darcy,D. Scott McMeekin,J. Tate Thigpen,Lisa M. Adler,Jonathan S. Berek,Julia Chapman,P. DiSilvestro,Ira R. Horowitz,James V. Fiorica +11 more
TL;DR: Trastuzumab as a single agent did not demonstrate activity against endometrial carcinomas with HER2 overexpression or HER2 amplification, although full planned accrual of women with Her2 amplified tumors was not achieved due to slow recruitment.
Journal ArticleDOI
Heightened Expression of Cyclooxygenase-2 and Peroxisome Proliferator-Activated Receptor-δ in Human Endometrial Adenocarcinoma
Beverly J. Tong,Jian Tan,Lovella Tajeda,Sanjoy K. Das,Julia Chapman,Raymond N. DuBois,Sudhansu K. Dey +6 more
TL;DR: This work describes for the first time the heightened expression of COX-2 and PPARdelta, but notCOX-1, in uterine endometrial adenocarcinoma.
Journal ArticleDOI
The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.
TL;DR: Antioxidants, when added adjunctively, to first-line chemotherapy, may improve the efficacy of chemotherapy and may prove to be safe.
Journal ArticleDOI
Estrogen replacement in surgical stage I and II endometrial cancer survivors
TL;DR: A retrospective review was performed of 123 women with surgical stage I and II endometrial adenocarcinoma treated between 1984 and 1994; 62 had received estrogen replacement therapy after cancer therapy as discussed by the authors.